{"title":"局部晚期直肠癌器官保存的新辅助治疗综述。","authors":"Liangting Qiu, Jianjun Li","doi":"10.2147/TCRM.S518959","DOIUrl":null,"url":null,"abstract":"<p><p>Preoperative chemoradiotherapy (CRT) and sphincter-preserving total mesorectal excision (TME) effectively control tumor growth in locally advanced rectal cancer (LARC). However, associated complications can impair the quality of life (QoL) of the patients. Neoadjuvant therapies, such as consolidation neoadjuvant therapy and total neoadjuvant therapy (TNT), can improve tumor regression, potentially achieving a complete response and allowing organ preservation. Emerging clinical data suggest that these approaches can promote long-term cancer control in patients with LARC.</p>","PeriodicalId":22977,"journal":{"name":"Therapeutics and Clinical Risk Management","volume":"21 ","pages":"1289-1293"},"PeriodicalIF":2.8000,"publicationDate":"2025-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12375309/pdf/","citationCount":"0","resultStr":"{\"title\":\"Neoadjuvant Therapy for Organ Preservation in Locally Advanced Rectal Cancer: A Review.\",\"authors\":\"Liangting Qiu, Jianjun Li\",\"doi\":\"10.2147/TCRM.S518959\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Preoperative chemoradiotherapy (CRT) and sphincter-preserving total mesorectal excision (TME) effectively control tumor growth in locally advanced rectal cancer (LARC). However, associated complications can impair the quality of life (QoL) of the patients. Neoadjuvant therapies, such as consolidation neoadjuvant therapy and total neoadjuvant therapy (TNT), can improve tumor regression, potentially achieving a complete response and allowing organ preservation. Emerging clinical data suggest that these approaches can promote long-term cancer control in patients with LARC.</p>\",\"PeriodicalId\":22977,\"journal\":{\"name\":\"Therapeutics and Clinical Risk Management\",\"volume\":\"21 \",\"pages\":\"1289-1293\"},\"PeriodicalIF\":2.8000,\"publicationDate\":\"2025-08-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12375309/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Therapeutics and Clinical Risk Management\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2147/TCRM.S518959\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q1\",\"JCRName\":\"Pharmacology, Toxicology and Pharmaceutics\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutics and Clinical Risk Management","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/TCRM.S518959","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
Neoadjuvant Therapy for Organ Preservation in Locally Advanced Rectal Cancer: A Review.
Preoperative chemoradiotherapy (CRT) and sphincter-preserving total mesorectal excision (TME) effectively control tumor growth in locally advanced rectal cancer (LARC). However, associated complications can impair the quality of life (QoL) of the patients. Neoadjuvant therapies, such as consolidation neoadjuvant therapy and total neoadjuvant therapy (TNT), can improve tumor regression, potentially achieving a complete response and allowing organ preservation. Emerging clinical data suggest that these approaches can promote long-term cancer control in patients with LARC.
期刊介绍:
Therapeutics and Clinical Risk Management is an international, peer-reviewed journal of clinical therapeutics and risk management, focusing on concise rapid reporting of clinical studies in all therapeutic areas, outcomes, safety, and programs for the effective, safe, and sustained use of medicines, therapeutic and surgical interventions in all clinical areas.
The journal welcomes submissions covering original research, clinical and epidemiological studies, reviews, guidelines, expert opinion and commentary. The journal will consider case reports but only if they make a valuable and original contribution to the literature.
As of 18th March 2019, Therapeutics and Clinical Risk Management will no longer consider meta-analyses for publication.
The journal does not accept study protocols, animal-based or cell line-based studies.